Herein, we present a 50-year-old hypertensive woman who uses sublingual captopril frequently and suffers from recurrent, reversible and painful oral mucositis that thought to be caused by sublingual captopril.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Captopril inhibits angiotensin-converting enzyme and it is the most used sub-lingual drug in emergency departments to decrease blood pressure.
📊
Key Findings & Data:Sublingual captopril is safe, effective and useful in treating hypertensive urgency.
💡
Conclusion & Impact:Herein, we present a 50-year-old hypertensive woman who uses sublingual captopril frequently and suffers from recurrent, reversible and painful oral mucositis that thought to be caused by sublingual captopril.
Captopril inhibits angiotensin-converting enzyme and it is the most used sub-lingual drug in emergency departments to decrease blood pressure. Sublingual captopril is safe, effective and useful in treating hypertensive urgency. However, it is known that captopril has fewer systemic and dermatologic side effects such as headache, weakness and oral ulcers, oral pemphigus, consecutively. No data is available about captopril induced oral mucositis. Herein, we present a 50-year-old hypertensive woman who uses sublingual captopril frequently and suffers from recurrent, reversible and painful oral mucositis that thought to be caused by sublingual captopril.
Adar, A., Önalan, O., Aktaş, H., Ertuğrul, S., Çakan, F. (2020). A very rare complication of sublingual captopril. Journal of Experimental and Clinical Medicine, Volume: 36 Issue: 3. https://ajindex.com/articles/1423361
Gemici, K., Y. Karakoc, A. Ersoy, I. I. Baran, S. Gullulu and J. Cordan (1999). "A Comparison of Safety and Efficacy of Sublingual Captopril with Sublingual Nifedipine in Hypertensive Crisis." Int J Angiol 8(3): 147-149.
Goswami, T., B. Jasti and X. Li (2008). "Sublingual drug delivery." Crit Rev Ther Drug Carrier Syst 25(5): 449-484.
Goswami, T., A. Kokate, B. R. Jasti and X. Li (2013). "In silico model of drug permeability across sublingual mucosa." Arch Oral Biol 58(5): 545-551.
Guerrera, G., D. Melina, L. Capaldi, R. Mauro, F. Colivicchi, C. Cardillo, G. Guerrera, V. Musumeci, L. Savi, A. Santoliquido and et al. (1990). "[Sublingually administered captopril versus nifedipine in hypertension emergencies]." Minerva Cardioangiol 38(1-2): 37-44.
Lombardi, M. L., E. de Angelis, F. Rossano and V. Ruocco (1993). "Imbalance between plasminogen activator and its inhibitors in thiol-induced acantholysis." Dermatology 186(2): 118-122.
Maleki, A., M. Sadeghi, M. Zaman, M. J. Tarrahi and B. Nabatchi (2011). "Nifedipine, Captopril or Sublingual Nitroglycerin, Which can Reduce Blood Pressure the Most?" ARYA Atheroscler 7(3): 102-105.
Narang, N. and J. Sharma (2011). "Sublingual mucosa as a route for systemic drug delivery." Journal of Pharmacy and Pharmaceutical Sciences, 3(2).
Shinkai, R. S., J. P. Hatch, C. B. Schmidt and E. A. Sartori (2006). "Exposure to the oral side effects of medication in a community-based sample." Spec Care Dentist 26(3): 116-120.
Wolf, R., A. Tamir and S. Brenner (1991). "Drug-induced versus drug-triggered pemphigus." Dermatologica 182(4): 207-210.